Nexam Chemical publishes information document in connection with rights issue

Nexam Chemical announced a rights issue of approximately SEK 51.8 million (before issue costs), resolved by the board on 22 December 2025 and approved by an extraordinary general meeting on 19 January 2026; the Information Document has been registered with the Swedish Financial Supervisory Authority and is available on the company website. Key dates include trading in subscription rights 26 Jan–4 Feb 2026, subscription period 26 Jan–9 Feb 2026, expected outcome announcement 11 Feb 2026 and registration with the Swedish Companies Registration Office in week 9 of 2026; Corpura is sole coordinator/bookrunner, Setterwalls legal adviser and Aqurat issuing agent. The release notes jurisdictional distribution restrictions, that no prospectus will be prepared, and contains standard forward‑looking and investor risk disclaimers.

Analysis

Market structure: The SEK 51.8m rights issue is dilutive and will mechanically pressure Nexam Chemical (STO:NEXAM) equity in the near term as new shares and subscription rights trade (26 Jan–9 Feb). Winners are existing large holders who can subscribe pro rata to avoid dilution and the coordinator/bookrunner (Corpura); losers are passive/foreign investors excluded by distribution restrictions and any short-term liquidity providers. The restricted distribution (many jurisdictions excluded) reduces addressable demand and likely increases bid-ask spreads and implied volatility over the subscription window.

Risk assessment: Tail risks include a failed rights take-up (<70% subscription) forcing bridge financing or insolvency, and foreign direct investment screening blocking a strategic investor—both could halve market value in weeks. Immediate (days) risk: price gap down during rights trading; short-term (weeks) risk: announcement on 11 Feb and registration in week 9; long-term (quarters) depends on execution of commercialization of polymer additives and order intake — cash burn vs. new contract conversion is the key metric.

Trade implications: For liquid accounts, consider a small directional trade: short up to 1–2% NAV in STO:NEXAM into the rights trading window (26 Jan–9 Feb) with stop at +10% and take-profit at -20% or on announcement (11 Feb). For holders, subscribe pro rata if your position >0.5% NAV to avoid >20% dilution; otherwise sell subscription rights into the market. If options exist, buy Mar/Apr puts (1–3% notional) to hedge downside through the outcome date.

Contrarian angle: The market may underprice the upside if the SEK 51.8m is sufficient to commercialize a single signed contract or scale a niche polymer product — if management publishes a firm order or revenue guidance within 2–3 months, the re-rating could be +30–100%. Conversely, liquidity constraints and FDI screening create structural illiquidity that can keep the stock depressed despite good fundamentals; this bifurcation favors option-based asymmetry trades rather than outright long exposure.

Key Decisions for Investors

• If you hold STO:NEXAM and your position >0.5% NAV: subscribe pro rata in the rights issue to avoid >20% dilution; commit cash now (deadline 9 Feb) and set target re-evaluation at the 11 Feb outcome announcement.
• For opportunistic short: establish a 1–2% NAV short in STO:NEXAM between 26 Jan–4 Feb (rights traded) with a hard stop at +10% and take-profit at -20% or flatten on 11 Feb; reduce size if daily ADV coverage <€100k (low liquidity).
• If options available: buy Mar/Apr put spreads (limit cost to 0.5–1.5% NAV) to capture volatility until the outcome announcement; prefer debit put spreads to cap premium outlay.
• Reallocate 1–3% from small-cap Swedish specialty chemical exposure into OMXSPI (index) or large-cap defensive industrials by 11 Feb to reduce idiosyncratic funding-event risk while preserving sector exposure.
• Monitor three binary catalysts over next 60 days: (1) rights take-up % (threshold: <80% = negative), (2) any disclosed commercial contracts/order intake (positive if >SEK 10–20m), and (3) outcome of FDI screening or any announced strategic investor (materially positive if strategic stake announced).